| Autor: |
Del Forno, Simona, Solfrini, Serena, Ferrini, Giulia, Zannoni, Letizia, Bertoldo, Valentina, Monti, Giorgia, Leonardi, Deborah, Labate, Antonio Maria Morselli, Paccapelo, Alexandro, Seracchioli, Renato |
| Zdroj: |
Journal of Endometriosis and Pelvic Pain Disorders; October 2013, Vol. 5 Issue: 4 p151-158, 8p |
| Abstrakt: |
Purpose To investigate the effect of a low-dose oral contraceptive containing drospirenone/ethinylestradiol 3 mg/20 μg on endometrioma mean diameter.Methods Fifty women with sonographic diagnosis of ovarian endometrioma and at least 12 months of therapy with drospirenone/ethinylestradiol 3 mg/20 μg, without previous adnexal surgery, were selected for this retrospective study. Endometrioma mean diameter measured with transvaginal ultrasonography and endometriosis-associated symptoms evaluated by a visual analogue scale (VAS) score (0-10) were reported at therapy prescription (baseline) and after 6, 12 and 18 months of treatment. Main outcome measures were endometrioma mean diameters and endometriosis-associated symptoms variations during the follow-up; differences between cyclic and continuous regimen were also considered.Results A significant reduction in endometrioma mean diameter was observed during the follow-up. The reductions of mean diameter versus baseline values were significantly higher in continuous users than in cyclic users at 6 and 18 months of follow-up. No new endometriomas occurred. The dysmenorrhea VAS score significantly decreased during the follow-up.Conclusions Drospirenone/ethinylestradiol 3 mg/20 μg seems to be effective in reducing endometrioma mean diameter. The continuous regimen seems to be associated with a greater reduction than the cyclic one. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
